AR and breast carcinoma: The Western blots illustrated that the isogenic SKBRM cell lines used in the in vivo and in vivo models did not express the androgen receptor to an appreciable extent, precluding KCZ and KCZ-7 from inhibiting tGLI1-positive breast cancer through androgen receptor antagonism (Supplementary Figure S8a).